Abstract. In addition to intracellular calcium, which activates myosin light chain (MLC) kinase, MLC phosphorylation and hence contraction is importantly regulated by MLC phosphatase (MLCP). Recent evidence suggests that distinct signaling cascades of vasoactive hormones interact with the Rho/Rho kinase (ROK) pathway, affecting the activity of MLCP. The present study measured the impact of ROK inhibition on vascular F-actin distribution and on vasoconstriction induced by activation/inhibition of distinct signaling pathways in vivo in the microcirculation of the split hydronephrotic rat kidney. 
A 1 agonist N 6 -cyclopentyladenosine (CPA) reduced glomerular blood flow (GBF) by about 50% through vasoconstriction at different vascular levels. ROK inhibition with Y-27632 or HA-1077, but not protein kinase C inhibition with Ro 31-8220, blunted ET B -induced vasoconstriction. Furthermore, the reduction of GBF and of vascular diameters in response to ODQ or CPA were abolished by pretreatment with Y-27632. ROK inhibitors prevented constriction of preglomerular vessels and of efferent arterioles with equal effectiveness. Confocal microscopy demonstrated that Y-27632 did not change F-actin content and distribution in renal vessels. The results suggest that ROK inhibition might be considered as a potent treatment of renal vasoconstriction, because it interferes with constriction induced by distinct signaling pathways in renal vessels without affecting F-actin structure. alessandro.cavarape@dpmsc.uniud.it
The primary signal for vascular smooth muscle cell (VSMC) contraction is an increase of intracellular calcium (Ca 2ϩ ) levels, activating myosin light chain (MLC) kinase, which leads to MLC phosphorylation (1) . In the past few years, evidence has accumulated that enhancement of Ca 2ϩ sensitivity of VSMC, involving inhibition of MLC phosphatase (MLCP), contributes to VSMC contraction importantly (2) . So far, two molecular mechanisms of MLCP inhibition have been uncovered (3) . First, receptor-mediated activation of the small G protein RhoA leads to activation of Rho kinase (ROK), which inhibits MLCP through phosphorylation of its regulatory subunit either directly or via ZIP-like kinase (4, 5) . Second, protein kinase C ␣ and ␦ isoforms have been identified to phosphorylate CPI-17, which, in the phosphorylated state, inhibits MLCP specifically (6, 7) . A recently developed ROK inhibitor, the pyridine derivative Y-27632, has been shown to potently inhibit the contraction of preparations from experimental animals and human arterial vessels induced by different agonists in vitro and also to correct arterial pressure to normotensive levels in different experimental models of hypertension in vivo (8 -11) . Because of the evidence that the Rho/ROK pathway mediates tonic vasoconstriction, ROK is thought to play a crucial role in human diseases, e.g., in hypertension and myocardial ischemia (12, 13) . The contribution of the ROK pathway to renal vasoconstriction is practically unknown.
A number of investigations have elucidated the role of a wide variety of circulating and locally produced vasoactive molecules in regulating renal hemodynamics under normal and pathologic conditions (14) . Vasoconstrictors bind to specific receptors to activate intracellular pathways triggering contraction of VSMC. Also in the kidney, VSMC tone is regulated by a complex network of constricting and dilating intracellular signaling cascades, some of which might modulate vasomotor tone in part independent of changes in intracellular Ca 2ϩ . Thus, renal vasoconstrictors could increase Ca 2ϩ sensitivity through MLCP inactivation mediated by ROK. Conversely, VSMC relaxation mediated by an increase in intracellular cAMP and cGMP is associated with a decrease of Ca 2ϩ sensitivity (3, 15) . Evidence has accumulated that cGMP-and cAMP-dependent protein kinases can directly increase the activity of MLCP and interfere with the Rho/ROK pathway (3). However, the role of ROK in renal vasoconstriction mediated by distinct signaling pathways has not yet been investigated.
In addition to smooth muscle contraction, the Rho/ROK pathway stimulates stress fiber formation and actin polymerization in cultured cells (16) . Accordingly, ROK inhibition with Y-27632 completely abolished stress fibers in cultured cells (11) . Though actin filament disruption has been demonstrated to severely impair vasoconstriction in isolated mesenteric arteries (17) , F-actin distribution in vessels has not yet been examined after ROK inhibition.
The aim of this study was to assess the influence of ROK on renal vasoconstriction at the microvascular level utilizing the in vivo model of the split hydronephrotic rat kidney. We employed different approaches to induce vasoconstriction through distinct intracellular pathways, namely phospholipase C activation, and reduction of intracellular cGMP or cAMP levels. Drug-induced constrictions in different renal vascular segments and reductions in glomerular blood flow (GBF) were measured under control conditions and after local application of the ROK inhibitors Y-27632 and HA-1077 as compared with PKC inhibition. Moreover, we also investigated the effect of ROK inhibition on actin filament organization in the renal vascular wall.
Materials and Methods

Preparation of the Hydronephrotic Kidney
The study protocols were performed on 29 female Wistar rats (210 to 240 g) in accordance with national animal protection guidelines. The animals had free access to food and water before the experiments. The technique and experimental procedures have been previously described in detail (18) . Briefly, unilateral surgical hydronephrosis was induced by permanently ligating the left ureter via a flank incision during pentobarbital sodium anesthesia (Nembutal, 60 mg/Kg intraperitoneally; Ceva, Bad Segeberg, Germany). The final experiments were performed under thiobutabarbital anesthesia (Inactin, 100 mg/kg intraperitoneally; Byk Gulden, Konstanz, Germany) 2 to 3 mo after induction of hydronephrosis. Each rat was placed on a 37°C heated surgical table. The trachea was intubated, and the left jugular vein was cannulated for the continuous replacement of isotonic saline at a rate of 60 l/min and for infusion of drugs. A polyethylene catheter was inserted into the left femoral artery for continuous measurements of systemic BP. The left hydronephrotic kidney was exposed through a flank incision and split carefully along the great curvature using a thermal cautery. The dorsal half of the split kidney was sutured to a semicircular-shaped wire frame. Blood supply and innervation remained intact after this preparation. The wire frame with the fixed split kidney was placed at the bottom of a specially designed Plexiglas chamber suitable for intravital transillumination microscopy. The entry of the renal hilus into the chamber was sealed with silicon grease, and the chamber was filled with 50 ml of an isotonic, isocolloidal solution (Hemaccel; Behringwerke AG, Marburg, Germany) maintained at a constant temperature of 37°C with a feedback-controlled heating system.
Videomicroscopy
The table was mounted on the microscope stage. Images of renal microvessels obtained through a special water-immersion objective (Ultropak UO-55; Leitz, Wetzlar, Germany) were visualized with a CCD camera, displayed on a calibrated monitor by a closed circuit TV system, and recorded on line on videotape. The luminal vessel diameters were measured directly from the monitor and were converted to in vivo diameters (expressed in micrometers) using a conversion factor to account for the magnification of the vessel images.
Vessel Segments and GBF
Measurements of the following vessel segments were carried out according to their branching pattern from the selected glomerulus: (1) proximal interlobular artery (near the arcuate artery); (2) distal interlobular artery (near the afferent arteriole); (3) proximal afferent arteriole (near the interlobular artery); (4) distal afferent arteriole (at a site within 100 m from the glomerulus); and (5) efferent arteriole (within 50 m from the glomerulus).
Velocity of red blood cells was measured in the efferent arteriole of the selected glomerulus by using a velocity-tracking correlator (Model 102B; IPM Inc., San Diego, CA). In this on-line computing system two photodiodes obtain photometric signals from the moving red blood cells (19) . To obtain the GBF value, the measured red cell velocity was multiplied by the luminal cross-section of the efferent arteriole and corrected for the Fahreus-Lindqvist effect (20) .
Experimental Protocols
After the surgical procedure, each kidney was allowed to adapt to the tissue bath conditions for at least 60 min. The stability of the preparation has been demonstrated for a duration of 3 h (21). Each protocol included several experimental periods at the end of which mean arterial pressure (MAP), vascular diameters, and GBF were measured. The first period served as baseline control.
Six series of experiments were performed. In the first series, dose-response experiments for Y-27632 were conducted. The other five experimental series started with control measurements during which the ET B receptor agonist IRL 1620 (group 1, n ϭ 6; group 2, n ϭ 5; group 3, n ϭ 5), the guanylyl cyclase inhibitor ODQ (group 4, n ϭ 6) or the selective A 1 adenosine receptor agonist N 6 -cyclopenthyladenosine (CPA) (group 5, n ϭ 7) were locally administered into the tissue bath to reduce GBF from a threshold value to about 50% by up to three sequentially increasing doses of vasoconstrictors. After wash out (30 min) and baseline measurements in the five experimental series, measurements were taken after intrarenal inhibition of ROK by local administration of the selective inhibitors Y-27632 or HA-1077 or after intrarenal inhibition of PKC by local administration of Ro 31-8220. After control measurements, during which the renovascular parameters were evaluated in a new baseline condition at the steady state, the effects of IRL 1620, ODQ, and CPA were assessed after intrarenal inhibition of ROK or PKC, whereby the doses of IRL 1620 and CPA were augmented in groups 1, 4, and 5 to obtain a reduction in GBF comparable to that detected during the pre-inhibition measurements. Measurements were taken about 10 min after application of IRL 1620 and CPA and about 15 min after application of ODQ, Y-27632, HA-1077, and Ro 31-8220, when a steady state had been reached.
For stimulation of PLC, the ET B agonist IRL 1620 was chosen, because we have demonstrated earlier that IRL 1620 induces not only preglomerular vasoconstriction but also marked efferent arteriolar constriction (22) . The effects of IRL 1620 and of A 1 receptor agonists have been shown to be fully reversible after washout (22) (23) (24) . Furthermore, vasoconstrictions induced by IRL 1620 and A 1 receptor agonists do not desensitize in the hydronephrotic kidney, as is the case for angiotensin II and diadenosine polyphosphates (22) (23) (24) (25) (26) . The reversibility of the ODQ-induced vasoconstriction was confirmed by wash out. To exclude that the renal vasculature desensitized in response to ODQ, the protocol was reversed (Y-27632 ϩ ODQ, washout, ODQ) in half of the experiments. We obtained similar results for ODQ with the normal and the reversed protocol; therefore, data were pooled together.
Y-27632 and HA-1077 have been reported to inhibit ROK with IC 50 values of 8 · 10 Ϫ7 M and 2 · 10 Ϫ6 M, respectively (27) .
Concentrations of 10
Ϫ5 M Y-27632 and 2 · 10 Ϫ5 M HA-1077 inhibit PKC␣ by 2% and 14%, respectively (27) . The IC 50 value of Ro 31-8220 for PKC␣ inhibition is 3 · 10 Ϫ8 M, whereas 1 M Ro 31-8220 reduces ROK activity by only 8% (27) .
It should be noted that the concentrations of vasoactive drugs, which are locally administered into the tissue bath, need to be about tenfold higher to elicit similar effects in the hydronephrotic kidney as compared with isolated or perfused preparations. For example, 10 Ϫ9 M ET-1 and 10 Ϫ8 M angiotensin II in the tissue bath constrict afferent arterioles by about 15%, whereas a similar diameter reduction is seen with 10 Ϫ10 M ET-1 and Ͻ10 Ϫ9 M angiotensin II in isolated rat afferent arterioles (28) or in isolated perfused hydronephrotic kidneys (29, 30) . There is most likely a steep concentration gradient for locally applied drugs between the tissue bath and the vessel lumen, because the hydronephrotic kidney has a considerable thickness (200 to 400 m) and the concentration of drugs in the blood stream is practically zero.
IRL 1620 (Alexis, Germany), CPA (Boehringer Mannheim, Germany), Y-27632 (kindly provided by Yoshitomi Pharmaceutical Inc.), and HA-1077 (Alexis, Germany) were dissolved in saline. ODQ and Ro 31-8220 (Alexis, Germany) were dissolved in DMSO; the final DMSO concentration in the tissue bath was below 0.1%. All the vasoactive drugs used in our experiments were administered into the tissue bath by local application to avoid any systemic effect on hemodynamic parameters.
Examination of F-Actin Distribution
Hydronephrotic kidneys were prepared for videomicroscopy as described above. Hydronephrotic kidneys were incubated with either vehicle (controls) or 10 Ϫ4 M Y-27632 for 30 min. Hydronephrotic kidneys were then excised and fixed in 2% paraformaldehyde for 2.5 h. The kidney tissue was cut in stripes, dehydrated in isopentane in liquid nitrogen, and mounted on styropor snips for cryosectioning. Kidney tissue was sectioned at 15-m thickness. Further procedures were identical to those as recently described (31) . Briefly, sections were permeabilized (0.3% Triton X-100), blocked for 1 h at room temperature in blocking solution (2% fetal bovine serum, 2% bovine serum albumin, 0.2% fish gelatin in phosphate buffered saline), and incubated with Alexa-conjugated phalloidin (Molecular Probes, Eugene, OR) to visualize F-actin. Specimen were viewed with a confocal laser scanning microscope (TCS-SP; Leica Microsystems, Heidelberg, Germany). To assess F-actin intensity, all images were taken with identical confocal microscope settings for laser power, photomultiplier gain, and pinhole size.
Statistical Analyses
Data are presented as mean Ϯ SEM. Changes in vascular diameters and GBF are expressed as percentage changes from the preceding control values. Paired and unpaired t test, ANOVA, and Bonferroni's method for multiple comparisons were used as appropriate to test for statistical significance. The data have been analyzed both as absolute and percent values. Values of P Ͻ 0.05 were considered statistically significant.
Results
Absolute values for measured parameters in five experimental groups under control conditions before and after application of inhibitors are listed in Table 1 . MAP was not affected by local administration of vasoconstrictors or inhibitors in all the experimental groups, and it remained stable throughout the experimental protocols if not otherwise indicated.
Effects of ROK and PKC Inhibitors on Basal Vessel Tone
In the first series of experiments, the effect of increasing concentrations of the ROK inhibitor Y-27632 (10 Ϫ7 to 10 Ϫ4 M) on the spontaneous, endogenous tone of the interlobular artery was determined ( Figure 1A ). In the interlobular artery, diameter did not change at 10 Ϫ7 and 10 Ϫ6 M Y-27632, but it significantly increased at higher concentrations (10 Ϫ5 and 10 
Effects of ET B Receptor Agonist (IRL 1620), Guanylyl Cyclase Inhibitor (ODQ), and Adenosine A 1 Receptor Agonist (CPA)
The effects of local application of IRL 1620, ODQ, and CPA on luminal diameters and on GBF in hydronephrotic rat kidneys are depicted in Figure 3 . The ET B receptor agonist (IRL 1620) at a local concentration of 10 Ϫ8 M constricted both preand postglomerular vessels and decreased GBF. The most pronounced vasoconstriction was observed in efferent arterioles, in agreement with earlier findings (22) . At a local concentration of 3 · 10 Ϫ5 M of the guanylyl cyclase inhibitor (ODQ), a stable reduction of GBF was reached within 15 min. The reduction in GBF was due to a rather homogenous vasoconstriction within the renal arteriolar network ranging from 11% to 19%. The adenosine A 1 receptor agonist (10 Ϫ5 M CPA) induced constriction selectively in preglomerular vessels. In accordance with earlier findings (23, 24) , the strongest vasoconstriction in response to CPA was observed in the distal segment of the afferent arteriole in close vicinity to the glomerulus. The effects of IRL 1620, ODQ, and CPA were completely reversible, with return of hemodynamic parameters to baseline values after wash out ( Table 1) .
Effects of ET B Receptor Agonist (IRL 1620) after ROK and PKC Inhibition
In the presence of the ROK inhibitor Y-27632, the ET B agonist-induced vasoconstriction was markedly blunted. As Table 1 . Absolute values for vessel diameters, glomerular blood flow (GBF), and MAP for the different experimental groups and for the pooled data of three shown in Figure 4 , the same concentration (10 Ϫ8 M) of the ET B agonist (IRL 1620) as applied in the beginning induced only small changes in GBF and in vessel diameters (Ͻ6%; P Ͼ 0.05) in the presence of the ROK inhibitor Y-27632. A tenfold higher concentration (10 Ϫ7 M) of the ET B agonist (IRL 1620) was required to obtain a distinct reduction in GBF, whereas vasoconstriction still remained weak (Ͻ17%, P Ͼ 0.05). Importantly, both efferent and preglomerular vasoconstriction in response to the ET B agonist (IRL 1620) were attenuated by the ROK inhibitor Y-27632 to a similar extent. The structurally different ROK inhibitor HA-1077 (10 Ϫ4 M) blunted ET B agonist-induced vasoconstriction in pre-and postglomerular vessels to a similar degree as Y-27632 ( Figure 5 ). In contrast, the PKC inhibitor Ro 31-8220 did not significantly affect ET B agonist-induced vasoconstriction ( Figure 5 ).
Effects of Guanylyl Cyclase Inhibitor (ODQ) and Adenosine A 1 Receptor Agonist (CPA) after ROK Inhibition
After ROK inhibition with Y-27632, vasoconstriction induced by the guanylyl cyclase inhibitor (3 · 10 Ϫ5 M ODQ) was completely abolished both in preglomerular vessels and in efferent arterioles ( Figure 6 . Data are mean Ϯ SEM; n ϭ 6 to 27 vessels of n ϭ 5 to 6 animals; * P Ͻ 0.05 significant diameter change; o P Ͻ 0.05 significant effect of inhibitor. ure 7). Specifically, the marked vasoconstriction located in the distal afferent arteriole in response to the adenosine A 1 agonist (CPA) under control conditions was completely abolished after ROK inhibition with Y-27632. However, there was a detectable decrease in GBF, indicating possible vasoconstriction further upstream in larger vessels, e.g., arcuate arteries. A tenfold higher concentration of the adenosine A 1 agonist (10 Ϫ4 M CPA) significantly constricted only the proximal interlobular artery in the presence of the ROK inhibitor Y-27632. At that high concentration, however, the adenosine A 1 agonist (CPA) evoked systemic effects, i.e., an increase in heart rate and severe hypotension, being mainly responsible for the large fall of GBF.
Effects of ROK Inhibition on F-Actin in Renal Vessels
Inhibition of ROK with Y-27632 has been shown to induce disassembly of stress fibers in cultured cells (11) . To test whether Y-27632 exerted its renal vasodilator effects via changes in content or structure of filamentous actin in renal arterioles, Y-27623 treated hydronephrotic kidneys were stained for F-actin and examined by confocal microscopy. F-actin intensity and structure did not differ between vessels of Y-27632-treated and control tissue (Figure 8) . Treatment with the ROK inhibitor Y-27632 affected actin filament structure in neither vascular smooth muscle cells (arrowheads in Figure 8 ) nor endothelial cells (arrows in Figure 8 ).
Discussion
In the present study, we demonstrate that inhibition of ROK blunts the constriction related to distinct signaling pathways in preglomerular vessels as well as in efferent arterioles. The investigation of the role of ROK in vasoconstriction in vivo became possible with the discovery of specific ROK inhibitors, i.e., HA-1077 (fasudil) (32) and Y-27632 (11) . Y-27632 is the most selective ROK inhibitor known, and it blocks MLC kinase only at concentrations above 250 M (11). Using these two ROK inhibitors it has been shown that inactivation of MLCP significantly contributes to regulation of vasomotor tone and blood flow in several tissues and organs (2) . However, the impact of ROK inhibition on the renal vasculature has been addressed in only one study so far, at a time when the molecular target of HA1077 was unknown (32) . Intravenous bolus injection of HA1077 increased renal blood flow by about 20% in anesthetized dogs (32) .
Endothelin exerts potent renal vasoconstrictor effects in vivo through activation of ET A and ET B receptors (18, 22) . Both ET A and ET B receptors are known to couple to several types of heterotrimeric G-proteins predominantly leading to PLC activation and intracellular Ca 2ϩ mobilization. ET-1 has been demonstrated to increase the amount of GTP-RhoA (33) and to induce most effective phosphorylation of MLC and contraction in bovine aortic VSMC (9) . Specifically, the ET B receptor is able to couple to G␣ 12/13 , which in turn activates RhoA (34) . Our results demonstrate an important role of ROK in mediating ET B -induced renal vasoconstriction. ET B receptor stimulation leads to marked efferent arteriolar constriction, which is blocked by Y-27632 or HA-1077; therefore, ROK-mediated constriction is clearly operative in efferent arterioles. In agreement with our findings, inhibition of the Rho/ROK pathway blunted ET-1-induced vasoconstriction in mammary, mesenteric, penile, cerebral, and coronary arteries (8, (35) (36) (37) (38) . Preventing coronary artery vasospasm in response to ET-1, ROK inhibition protected against myocardial ischemia in rabbits (13, 39) .
The PKC inhibitor Ro 31-8220 dilated pre-and postglomerular vessels, being equally effective as ROK inhibitors in the efferent arteriole but less effective in the interlobular artery ( Figure 2) . Thus, part of the basal tone in vessels of the hydronephrotic kidney in vivo is due to activation of PKC. Despite the reduction of basal vessel tone, PKC inhibition with Ro 31-8220 failed to prevent ET B -induced vasoconstriction in our experiments. The ability of PKC to induce constriction of afferent and efferent arterioles has been demonstrated by stimulating PKC with phorbol ester and a diacylglycerol analogue (40) . However, selective inhibitors of PKC did not affect norepinephrine-and 20-HETE-induced constriction of isolated interlobar and interlobular arteries, respectively (41, 42) , suggesting limited or selective activation of PKC by vasoconstrictors. Furthermore, the inability of Ro 31-8220 to inhibit ET Binduced vasoconstriction clearly demonstrates that the effects of ROK inhibitors Y-27632 and HA-1077 occurred independently of the PKC pathway.
The adenosine A 1 receptor decreases intracellular cAMP levels through G i protein coupling and has a unique function in the kidney in that it mediates the tubuloglomerular feedback (43) . Consistent with this notion, the adenosine A 1 receptor agonist CPA induced marked vasoconstriction in the distal segment of the afferent arteriole, which was sensitive to ROK inhibition in the present study. Besides cAMP, the cyclic nucleotide cGMP importantly regulates renal vessel tone being the second messenger of natriuretic peptides and NO (44) . Inhibition of soluble guanylyl cyclase by ODQ induced a strong vasoconstriction of preglomerular vessels and efferent arterioles in our present study, comparable to the effects of NO synthesis blockade by L-NAME (45) . Likewise, Trottier et al. (46) reported that ODQ completely inhibits the renal vasodilation evoked by endogenous NO. Similar to the effect of ROK inhibition on vasoconstriction elicited by reduced cAMP levels, Y-27632 blocked renal vasoconstriction when cGMP levels were lowered by ODQ.
There are several targets in the pathways of agonist-induced MLC phosphorylation that can be inhibited by cAMP-and cGMP-dependent kinases (2,3). Thus, changes in intracellular cAMP and cGMP levels result in more or less pronounced changes of vasomotor tone depending on the current degree of MLC phophorylation. Our observation that decreasing cAMP or cGMP levels failed to induce vasoconstriction in the presence of the ROK inhibitor Y-27632 could be interpreted in a way that both nucleotides interfere with the Rho/ROK pathway. Indeed it has been shown that both cAMP-and cGMPdependent kinases inhibit the Rho/ROK pathway via serine phosphorylation of RhoA (47) (48) (49) . On the other hand, in our study ROK inhibition could have lowered the level of MLC phosphorylation to such an extent that reduction of cAMP or cGMP was no longer able to induce vasoconstriction through disinhibition of pathways unrelated to the Rho/ROK pathway. In any case, our results indicate that ROK inhibition impairs vasoconstriction mediated by cAMP and cGMP pathways.
Besides MLCP, ROK also inactivates LIM kinase, thereby inhibiting actin depolymerization (16) . Consequently, ROK inhibition has been shown to consistently cause disassembly of stress fibers and a decrease of the F-to G-actin ratio in various cultured cell types, including VSMC (11, 50) . Matrougui et al. (17) demonstrated that ROK inhibition as well as actin filament disruption by cytochalasin B abolished the contractile response of isolated mesenteric arteries to angiotensin II. For the first time, our experiments provide evidence that ROK inhibition results in vasodilation without affecting F-actin organization in vessels in vivo. Additional downstream effectors of RhoA (e.g., mDia) (16), which stimulate actin polymerization, might be responsible for the maintenance of the actin cytoskeleton in VSMC during ROK inhibition in vivo.
In their first report on Y-27632, Uehata et al. (11) have already described that ROK inhibition induces stronger reductions in arterial BP in hypertensive as compared with normotensive rats. Recently, this finding has been extended to humans, in that the increase in forearm blood flow induced by the ROK inhibitor HA-1077 was about twofold higher in hypertensive patients as compared with normotensive subjects (12) . There are two findings suggesting a potential therapeutic benefit of ROK inhibition in the renal vasculature. First, lovastatin reduces the level of Rho proteins in renal vessels of hypertensive rats (51) . Second, enhanced activation of phospholipase D by angiotensin II in renal VSMC of hypertensive rats is sensitive to blockade of the Rho/ROK pathway (52) . The fact that ROK inhibition blunted vasoconstriction in preglomerular ves-sels as well as in efferent arterioles is of therapeutic relevance and contrasts with the action of Ca 2ϩ antagonists, which are without effect on L-type channel-lacking efferent arterioles (53, 54) .
In conclusion, we demonstrate that ROK inhibitors blunt renal vasoconstriction evoked by distinct signaling pathways without affecting vascular F-actin organization in vivo.
